Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival

Purpose: Radioligand therapy with [<sup>177</sup>Lu]PSMA-617 (PSMA-RLT) is a promising therapeutic option for metastatic castration-resistant prostate cancer (mCPRP). This study assessed the prognostic value of early PSA measurements during PSMA-RLT. Methods: 27 patients with mCRPC sched...

Full description

Bibliographic Details
Main Authors: Felix Kind, Thomas F. Fassbender, Geoffroy Andrieux, Melanie Boerries, Philipp T. Meyer, Juri Ruf
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
castration refractory metastatic prostate cancer
PSMA
PSA
radioligand therapy
[<sup>177</sup>Lu]PSMA-617
Online Access:https://www.mdpi.com/2072-6694/14/1/149

Similar Items

Similar Items